Bavarian Nordic Reports Significant Financial Growth in Q1
COPENHAGEN, Denmark – Bavarian Nordic A/S (OMX: BAVA) has shared exciting interim financial results for the first quarter of 2025, reflecting remarkable growth and continued commitment to public health through its innovative vaccine solutions.
Impressive Revenue Growth
In the first three months of 2025, Bavarian Nordic experienced a substantial increase in revenue, which escalated by 62% to DKK 1,347 million. This growth is attributed to the robust performance in both the Travel Health and Public Preparedness segments, indicating a successful strategy and heightened demand for the company’s offerings.
Travel Health Performance
The Travel Health segment showcased a notable 52% increase, achieving DKK 680 million in revenue. This surge stems primarily from heightened demand for vaccines such as those for rabies and tick-borne encephalitis (TBE), proving the company's ability to meet urgent global health needs.
Public Preparedness Gains
Public Preparedness saw an impressive 83% revenue growth, reaching DKK 629 million. This exceeded initial expectations due to proactive efforts to expedite the delivery of significant orders. Such advancements highlight Bavarian Nordic's effectiveness in scaling operations to align with national health initiatives.
Strong EBITDA Growth
Operating profit (EBITDA) for the quarter stood at DKK 420 million, translating to a 31% EBITDA margin. This robust financial outcome reflects the company's ability to manage costs efficiently while driving revenue growth.
Positive Financial Guidance
Bavarian Nordic maintained its financial guidance for the full year, projecting revenues between DKK 5,700 million and DKK 6,700 million, alongside an EBITDA margin between 26% and 30%. This commitment illustrates confidence in ongoing operations and future opportunities.
Highlights of Innovative Products
Travel Health
- Approval and launch of Vimkunya, the first-virus like particle chikungunya vaccine, in the US and EU, marking a pivotal moment in vaccine availability for those aged 12 and older.
- Strategic partnership formed with Biological E. Limited aimed at supplying chikungunya vaccines to low- and middle-income countries.
- Regulatory submissions initiated in the UK and Canada, showcasing the company's readiness to extend its global health impact.
Public Preparedness Initiatives
- FDA approval for the freeze-dried version of JYNNEOS, used for smallpox and mpox prevention among adults, marking a key advancement in Bavarian Nordic's commitment to public health preparedness.
Recent Developments After Reporting
Following the reporting date, significant progress has been made in associations with public health bodies, including a recommendation from the U.S. CDC’s ACMI for the recommended use of Vimkunya for individuals traveling to areas at risk of chikungunya virus outbreaks.
Engagement with Investors
Bavarian Nordic is dedicated to maintaining transparent communication with its investors and stakeholders. The management hosted a call to discuss the interim results and future strategies aimed at enhancing investor engagement.
Contact Information
For Investor Relations:
Rolf Sass Sørensen, Vice President Investor Relations,
Email: rss@bavarian-nordic.com, Tel: +45 61 77 47 43
For Media Inquiries:
Nicole Seroff, Vice President Corporate Communications,
Email: nise@bavarian-nordic.com, Tel: +45 53 88 06 03
Frequently Asked Questions
What are Bavarian Nordic's recent financial results?
Bavarian Nordic reported a 62% increase in revenue for Q1 2025, totaling DKK 1,347 million.
What product advancements have been made by Bavarian Nordic?
Vimkunya, a new chikungunya vaccine, was launched in both the US and EU, addressing significant global health concerns.
How is Bavarian Nordic contributing to public health?
Through innovative vaccine solutions and partnerships, Bavarian Nordic is enhancing global preparedness against diseases like chikungunya.
What is the company's financial guidance for 2025?
The company projects a revenue range of DKK 5,700 million to DKK 6,700 million for the full year.
Who can I contact for investor relations?
Investors can reach out to Rolf Sass Sørensen at rss@bavarian-nordic.com.
